Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. 1991

G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
Istituto di Clinica Medica II, University of Florence, Italy.

In a randomized double-blind trial we compared the effects of torasemide, a new loop diuretic, and furosemide in nonazotemic cirrhotic patients with ascites during a 3-day period in association with potassium canrenoate (200 mg/day) administration. Doses of loop diuretics administered in this trial (10 and 25 mg/day of torasemide and furosemide, respectively) had been shown to be equipotent in healthy subjects. Torasemide induced significantly greater natriuresis than furosemide (p less than 0.02), with a twofold greater percentage increase in basal values (day 1: 130% vs. 50%; day 2: 104% vs. 42%; and day 3: 65% vs. 26%, respectively). Body weight loss was significantly higher during torasemide (p less than 0.02) administration, and the overall decrease at the end of the treatment was twice as high for furosemide (2.5 +/- 0.6 kg vs. 1.3 +/- 0.4 kg, respectively). Diuresis was also higher during torasemide administration, but the difference was not significant (p = 0.08). The extent of kaliuresis observed during the two treatments was almost identical despite the striking differences in the natriuretic response. The effects of the two treatments on plasma electrolytes, creatinine clearance, blood urea nitrogen, mean arterial pressure, heart rate and plasma arginine vasopressin concentration were similar. Both drugs caused increases in plasma renin activity at the end of the treatment, whereas plasma aldosterone concentration slightly increased only after torasemide administration. Despite the presence of a trend toward a more pronounced effect on these parameters after torasemide administration, no significant difference between the two treatments was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077786 Torsemide A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION. 1-Isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea,1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea,Demadex,Torasemide
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
March 1997, Minerva medica,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
January 1986, European journal of clinical pharmacology,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
July 1993, The Clinical investigator,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
March 1993, Journal of hepatology,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
January 2013, Annals of hepatology,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
January 1994, Hepatology (Baltimore, Md.),
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
November 1982, Archives internationales de pharmacodynamie et de therapie,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
September 1998, Journal of hepatology,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
June 1988, Gastroenterology,
G Laffi, and F Marra, and G Buzzelli, and G Azzena, and E Meacci, and M L De Feo, and G La Villa, and P Gentilini
April 2006, Journal of clinical gastroenterology,
Copied contents to your clipboard!